Sugi Predict

Sugi Predict / Compounds / SCHEMBL7181127

SCHEMBL7181127

SCHEMBL7181127

Cc1cccc(C)c1C(=O)[PH](=O)CCCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR52 Q9Y2T5 1/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.44
▸ HPGD P15428 3/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ HDAC3 O15379 2/20 0.42
▸ HDAC4 P56524 2/20 0.42
▸ HDAC1 Q13547 2/20 0.42
▸ HDAC7 Q8WUI4 2/20 0.42
▸ HDAC2 Q92769 2/20 0.42
▸ HDAC10 Q969S8 2/20 0.42
▸ HDAC11 Q96DB2 2/20 0.42
▸ HDAC8 Q9BY41 2/20 0.42
▸ HDAC6 Q9UBN7 2/20 0.42
▸ HDAC9 Q9UKV0 2/20 0.42
▸ HDAC5 Q9UQL6 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ ADRA1A P35348 1/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ P2RX7 Q99572 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180908 0.95 GPR52 (0.47) GPR52SMN1; SMN2HPGDL3MBTL1HDAC3
SCHEMBL7179501 0.94 GPR52 (0.46) GPR52SMN1; SMN2HPGDL3MBTL1HDAC3
SCHEMBL7177345 0.94 GPR52 (0.46) GPR52SMN1; SMN2HPGDL3MBTL1HDAC3
SCHEMBL7185580 0.94 GPR52 (0.46) GPR52SMN1; SMN2HPGDL3MBTL1HDAC3
SCHEMBL7182719 0.94 GPR52 (0.46) GPR52SMN1; SMN2HPGDL3MBTL1HDAC3
SCHEMBL7177826 0.94 GPR52 (0.46) GPR52SMN1; SMN2HPGDL3MBTL1HDAC3
SCHEMBL7186889 0.91 GPR52 (0.50) GPR52SMN1; SMN2HPGDL3MBTL1KMT2A
SCHEMBL7183560 0.90 GPR52 (0.43) GPR52SMN1; SMN2HPGDL3MBTL1HDAC3
SCHEMBL7182295 0.88 SMN1; SMN2 (0.45) SMN1; SMN2HPGDL3MBTL1HDAC3HDAC4
SCHEMBL7187054 0.86 SCN5A (0.44) GPR52SMN1; SMN2HPGDL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 GPR52 3194/4885SMN1; SMN2 2939/4885HPGD 3983/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 GPR52 3263/4885SMN1; SMN2 3105/4885HPGD 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.